Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10438961 | 0.86 | KMT2A (0.48) | MAOAMAOBKMT2AALDH1A1HPGD | |
| SCHEMBL14886174 | 0.82 | MAOA (0.58) | MAOAMAOBNOTUMKMT2AMEN1 | |
| SCHEMBL10968507 | 0.71 | MAOA (0.52) | MAOAMAOBNOTUMKMT2AMEN1 | |
| SCHEMBL20642095 | 0.69 | ALDH1A1 (0.45) | MAOAMAOBNOTUMRXFP1ALDH1A1 | |
| SCHEMBL20834251 | 0.69 | MAOA (0.39) | MAOAMAOBNOTUMRXFP1KMT2A | |
| SCHEMBL11983592 | 0.69 | NOTUM (0.48) | MAOAMAOBNOTUMRXFP1KMT2A | |
| SCHEMBL3599815 | 0.69 | NOTUM (0.48) | MAOAMAOBNOTUMRXFP1KMT2A | |
| SCHEMBL14573056 | 0.69 | MAOA (0.56) | MAOAMAOBNOTUMRXFP1KMT2A | |
| SCHEMBL130712 | 0.69 | MAOA (0.71) | MAOAMAOBNOTUMRXFP1ALDH1A1 | |
| SCHEMBL3402653 | 0.69 | NOTUM (0.48) | MAOAMAOBNOTUMRXFP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192677-A1 | CYP11A1 INHIBITORS | ORION CORPORATION (FI) | 2023-06-22 | — | — | US | disclosed |
| US-11518745-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | ALKERMES PHARMA IRELAND LIMITED (IE) | 2022-12-06 | — | — | US | disclosed |
| WO-2021229152-A1 | CYP11A1 INHIBITORS | ORION CORPORATION (FI) | 2021-11-18 | — | — | WO | disclosed |
| EP-3558981-B1 | PYRAN DERIVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | ORION CORP (FI) | 2021-05-26 | — | — | EP | disclosed |
| EP-3798214-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2021-03-31 | — | — | EP | disclosed |
| US-20200407320-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-12-31 | — | — | US | disclosed |
| US-10723728-B2 | Prodrugs of Nh-acidic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2020-07-28 | — | — | US | disclosed |
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| WO-2018115591-A1 | PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | ORION CORPORATION (FI) | 2018-06-28 | — | — | WO | disclosed |
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-05-24 | — | — | US | disclosed |
| EP-3038466-B1 | 2,2-DIFLUORODIOXOLO A2A RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2018-05-23 | — | — | EP | disclosed |
| WO-2008060626-A9 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | HYDRA BIOSCIENCES INC (US) | 2008-07-31 | — | — | WO | disclosed |
| WO-2008060626-A2 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | HYDRA BIOSCIENCES, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192677-A1 | CYP11A1 INHIBITORS | CYP11B1, CYP11B2, CYP17A1 | MAOA 285/4885MAOB 313/4885NOTUM 1462/4885 |
| US-20200407320-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | MAOA 24/4885MAOB 9/4885NOTUM 2473/4885 |
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | NR1H4, FXR1, SLC10A1 | MAOA 3834/4885MAOB 3740/4885NOTUM 1474/4885 |
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | NR1H4, FXR1, SLC10A1 | MAOA 3834/4885MAOB 3740/4885NOTUM 1474/4885 |
| US-10723728-B2 | Prodrugs of Nh-acidic compounds | SI, NAAA, NIT2 | MAOA 1635/4885MAOB 2121/4885NOTUM 295/4885 |
| US-11518745-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | GABBR1, GABBR2, GABRE | MAOA 24/4885MAOB 9/4885NOTUM 2473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.